3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow ThromboGenics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Ocriplasmin, Sham injection - Vitreomacular Adhesion Including Macular Hole | Phase 3 | Completed | ThromboGenics | 220 | 2011-10-01 | 2016-03-14 |
| Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. Ocriplasmin 125µg, Placebo - Vitreomacular Adhesion | Phase 3 | Completed | ThromboGenics | 326 | 2008-12-01 | 2014-12-17 |
| Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. 125 µg Ocriplasmin, Placebo - Vitreomacular Adhesion | Phase 3 | Completed | ThromboGenics | 326 | 2008-12-01 | 2014-12-17 |
microplasmin (3) · salicylhydroxamic acid (1)
United States (3) · Belgium (1) · Czechia (1) · Germany (1) · Poland (1) · Spain (1) · United Kingdom (1)
PMID 22879421, PMID 22894573, PMID 23033391, PMID 26068086, PMID 30350717, PMID 34250257